2026/01/09 by Lisa Takahashi, Hirofumi Tomiyama, Hiroki Kobori +7 · 1 voice
Medicine · Biochemistry, Genetics and Molecular Biology · #Cardiomyopathy and Myosin Studies #Muscle Physiology and Disorders #Viral Infections and Immunology Research
paper · doi:10.1016/j.jphyss.2026.100055
openalex publication_date 2026/01/09 · openalex created_date 2026/01/10 · openalex updated_date 2026/08/01
Atherosclerosis leads to severe clinical complications, and biomarkers for asymptomatic atherosclerosis are desired. Plasma levels of myosin-11 have been reported to increase in patients with symptomatic atherosclerosis. To investigate the association between circulating myosin-11 levels and atherosclerotic cardiovascular disease (ASCVD) risk in patients without symptomatic atherosclerosis, this study recruited 161 participants: 80 patients with ASCVD risk, 50 patients with ischemic heart disease (IHD), and 31 control participants (Controls). We developed an ELISA that consists of rat monoclonal antibodies specific for the coiled-coil domain of myosin-11. Myosin-11 levels were highest in the IHD group, followed by the ASCVD risk group. The area under the receiver-operating characteristic curve of myosin-11 was 0.980 for IHD versus Controls and 0.874 for ASCVD risk versus Controls. The association between myosin-11 levels and hypertension remained significant after multivariate logistic regression analysis. Myosin-11 levels may be a biomarker for stratification of asymptomatic individuals with ASCVD risk.